活性氧在癌症治疗中的发病机理和机制的最新进展和未来方向。

IF 2.3 4区 医学 Q3 ONCOLOGY
Pathology & Oncology Research Pub Date : 2023-10-18 eCollection Date: 2023-01-01 DOI:10.3389/pore.2023.1611415
Priyanka Verma, Bhavika Rishi, Noreen Grace George, Neetu Kushwaha, Himanshu Dhandha, Manpreet Kaur, Ankur Jain, Aditi Jain, Sumita Chaudhry, Amitabh Singh, Fouzia Siraj, Aroonima Misra
{"title":"活性氧在癌症治疗中的发病机理和机制的最新进展和未来方向。","authors":"Priyanka Verma,&nbsp;Bhavika Rishi,&nbsp;Noreen Grace George,&nbsp;Neetu Kushwaha,&nbsp;Himanshu Dhandha,&nbsp;Manpreet Kaur,&nbsp;Ankur Jain,&nbsp;Aditi Jain,&nbsp;Sumita Chaudhry,&nbsp;Amitabh Singh,&nbsp;Fouzia Siraj,&nbsp;Aroonima Misra","doi":"10.3389/pore.2023.1611415","DOIUrl":null,"url":null,"abstract":"<p><p>A class of exceptionally bioactive molecules known as reactive oxygen species (ROS) have been widely studied in the context of cancer. They play a significant role in the etiopathogenesis for cancer. Implication of ROS in cancer biology is an evolving area, considering the recent advances; insights into their generation, role of genomic and epigenetic regulators for ROS, earlier thought to be a chemical process, with interrelations with cell death pathways- Apoptosis, ferroptosis, necroptosis and autophagy has been explored for newer targets that shift the balance of ROS towards cancer cell death. ROS are signal transducers that induce angiogenesis, invasion, cell migration, and proliferation at low to moderate concentrations and are considered normal by-products of a range of biological activities. Although ROS is known to exist in the oncology domain since time immemorial, its excessive quantities are known to damage organelles, membranes, lipids, proteins, and nucleic acids, resulting in cell death. In the last two decades, numerous studies have demonstrated immunotherapies and other anticancer treatments that modulate ROS levels have promising <i>in vitro</i> and <i>in vivo</i> effects. This review also explores recent targets for therapeutic interventions in cancer that are based on ROS generation or inhibition to disrupt the cell oxidative stress balance. Examples include-metabolic targets, targeted therapy with biomarkers, natural extracts and nutraceuticals and targets developed in the area of nano medicine. In this review, we present the molecular pathways which can be used to create therapy plans that target cancer by regulating ROS levels, particularly current developments and potential prospects for the effective implementation of ROS-mediated therapies in clinical settings. The recent advances in complex interaction with apoptosis especially ferroptosis and its role in epigenomics and modifications are a new paradigm, to just mechanical action of ROS, as highlighted in this review. Their inhibition by nutraceuticals and natural extracts has been a scientific challenging avenue that is explored. Also, the inhibition of generation of ROS by inhibitors, immune modulators and inhibitors of apoptosis and ferroptosis is explored in this review.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618351/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment.\",\"authors\":\"Priyanka Verma,&nbsp;Bhavika Rishi,&nbsp;Noreen Grace George,&nbsp;Neetu Kushwaha,&nbsp;Himanshu Dhandha,&nbsp;Manpreet Kaur,&nbsp;Ankur Jain,&nbsp;Aditi Jain,&nbsp;Sumita Chaudhry,&nbsp;Amitabh Singh,&nbsp;Fouzia Siraj,&nbsp;Aroonima Misra\",\"doi\":\"10.3389/pore.2023.1611415\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A class of exceptionally bioactive molecules known as reactive oxygen species (ROS) have been widely studied in the context of cancer. They play a significant role in the etiopathogenesis for cancer. Implication of ROS in cancer biology is an evolving area, considering the recent advances; insights into their generation, role of genomic and epigenetic regulators for ROS, earlier thought to be a chemical process, with interrelations with cell death pathways- Apoptosis, ferroptosis, necroptosis and autophagy has been explored for newer targets that shift the balance of ROS towards cancer cell death. ROS are signal transducers that induce angiogenesis, invasion, cell migration, and proliferation at low to moderate concentrations and are considered normal by-products of a range of biological activities. Although ROS is known to exist in the oncology domain since time immemorial, its excessive quantities are known to damage organelles, membranes, lipids, proteins, and nucleic acids, resulting in cell death. In the last two decades, numerous studies have demonstrated immunotherapies and other anticancer treatments that modulate ROS levels have promising <i>in vitro</i> and <i>in vivo</i> effects. This review also explores recent targets for therapeutic interventions in cancer that are based on ROS generation or inhibition to disrupt the cell oxidative stress balance. Examples include-metabolic targets, targeted therapy with biomarkers, natural extracts and nutraceuticals and targets developed in the area of nano medicine. In this review, we present the molecular pathways which can be used to create therapy plans that target cancer by regulating ROS levels, particularly current developments and potential prospects for the effective implementation of ROS-mediated therapies in clinical settings. The recent advances in complex interaction with apoptosis especially ferroptosis and its role in epigenomics and modifications are a new paradigm, to just mechanical action of ROS, as highlighted in this review. Their inhibition by nutraceuticals and natural extracts has been a scientific challenging avenue that is explored. Also, the inhibition of generation of ROS by inhibitors, immune modulators and inhibitors of apoptosis and ferroptosis is explored in this review.</p>\",\"PeriodicalId\":19981,\"journal\":{\"name\":\"Pathology & Oncology Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618351/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology & Oncology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/pore.2023.1611415\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology & Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2023.1611415","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在癌症的背景下,一类被称为活性氧(ROS)的异常生物活性分子已被广泛研究。它们在癌症的发病机制中起着重要作用。考虑到最近的进展,ROS在癌症生物学中的含义是一个不断发展的领域;对它们的产生、ROS的基因组和表观遗传学调节因子的作用的深入了解,早期被认为是一个化学过程,与细胞死亡途径相互关系-细胞凋亡、脱铁性细胞凋亡、坏死性细胞凋亡和自噬已被探索为将ROS平衡转移到癌症细胞死亡的新靶点。ROS是在低至中等浓度下诱导血管生成、侵袭、细胞迁移和增殖的信号转导子,被认为是一系列生物活性的正常副产物。尽管ROS自古以来就存在于肿瘤学领域,但其过量会破坏细胞器、膜、脂质、蛋白质和核酸,导致细胞死亡。在过去的二十年里,大量研究表明,调节ROS水平的免疫疗法和其他抗癌疗法在体外和体内都有很好的效果。这篇综述还探讨了癌症治疗干预的最新靶点,这些靶点基于ROS的产生或抑制来破坏细胞氧化应激平衡。例子包括代谢靶点、生物标志物靶向治疗、天然提取物和营养品以及纳米医学领域开发的靶点。在这篇综述中,我们介绍了可用于制定通过调节ROS水平靶向癌症的治疗计划的分子途径,特别是ROS介导的治疗在临床环境中有效实施的最新进展和潜在前景。与细胞凋亡,特别是脱铁性细胞凋亡的复杂相互作用及其在表观基因组学和修饰中的作用的最新进展是一种新的范式,而不仅仅是ROS的机械作用,正如本文所强调的那样。通过营养品和天然提取物抑制它们一直是一条具有科学挑战性的途径。此外,本文还探讨了抑制剂、免疫调节剂以及凋亡和脱铁性贫血抑制剂对ROS产生的抑制作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment.

Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment.

Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment.

Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment.

A class of exceptionally bioactive molecules known as reactive oxygen species (ROS) have been widely studied in the context of cancer. They play a significant role in the etiopathogenesis for cancer. Implication of ROS in cancer biology is an evolving area, considering the recent advances; insights into their generation, role of genomic and epigenetic regulators for ROS, earlier thought to be a chemical process, with interrelations with cell death pathways- Apoptosis, ferroptosis, necroptosis and autophagy has been explored for newer targets that shift the balance of ROS towards cancer cell death. ROS are signal transducers that induce angiogenesis, invasion, cell migration, and proliferation at low to moderate concentrations and are considered normal by-products of a range of biological activities. Although ROS is known to exist in the oncology domain since time immemorial, its excessive quantities are known to damage organelles, membranes, lipids, proteins, and nucleic acids, resulting in cell death. In the last two decades, numerous studies have demonstrated immunotherapies and other anticancer treatments that modulate ROS levels have promising in vitro and in vivo effects. This review also explores recent targets for therapeutic interventions in cancer that are based on ROS generation or inhibition to disrupt the cell oxidative stress balance. Examples include-metabolic targets, targeted therapy with biomarkers, natural extracts and nutraceuticals and targets developed in the area of nano medicine. In this review, we present the molecular pathways which can be used to create therapy plans that target cancer by regulating ROS levels, particularly current developments and potential prospects for the effective implementation of ROS-mediated therapies in clinical settings. The recent advances in complex interaction with apoptosis especially ferroptosis and its role in epigenomics and modifications are a new paradigm, to just mechanical action of ROS, as highlighted in this review. Their inhibition by nutraceuticals and natural extracts has been a scientific challenging avenue that is explored. Also, the inhibition of generation of ROS by inhibitors, immune modulators and inhibitors of apoptosis and ferroptosis is explored in this review.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
134
审稿时长
4-8 weeks
期刊介绍: Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信